Mortality and morbidity in transsexual subjects treated with cross-sex hormones.
about
Long-term follow-up of transsexual persons undergoing sex reassignment surgery: cohort study in SwedenHIV prevalence, risk behaviors, health care use, and mental health status of transgender persons: implications for public health interventionHealth care utilization, barriers to care, and hormone usage among male-to-female transgender persons in New York CityClinical management of transsexual subjectsGender and vascular reactivity.Testosterone dose-response relationships with cardiovascular risk markers in androgen-deficient women: a randomized, placebo-controlled trial.Effects of dehydroepiandrosterone (DHEA) on cardiovascular risk factors in older women with frailty characteristics.Suicide and suicide risk in lesbian, gay, bisexual, and transgender populations: review and recommendationsBalancing benefits and harm: chemical use and bodily transformation among Indonesia's transgender waria.Medical management of adult transsexual persons.Risk factors associated with cardiovascular events during testosterone administration in older men with mobility limitation.Gonadal suppressive and cross-sex hormone therapy for gender dysphoria in adolescents and adults.Cross-sex hormone use, functional health and mental well-being among transgender men (Toms) and Transgender Women (Kathoeys) in Thailand.A review of the physical and metabolic effects of cross-sex hormonal therapy in the treatment of gender dysphoria.Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness.HIV prevalence, risk behavior, hormone use and surgical history among transgender persons in Thailand.Estrogens, progestogens and thrombosis.Endocrine intervention for transsexuals.Gender identity disorder: treatment and post-transition care in transsexual adults.Androgen therapy and atherosclerotic cardiovascular disease.Long-Term Follow-Up of Individuals Undergoing Sex-Reassignment Surgery: Somatic Morbidity and Cause of DeathAgeing, oestrogen, platelets and thrombotic risk.Current management of male-to-female gender identity disorder in the UK.Long-term cross-sex hormone treatment is safe in transsexual subjects.Surveying the attitudes of transsexual patients referring to Tehran Institute of Psychiatry toward doctors' empathy, Iran, 2011-2012.Vascular actions of estrogens: functional implications.Physical victimization, gender identity and suicide risk among transgender men and women.The effects of endogenous and exogenous androgens on cardiovascular disease risk factors and progression.The safety of postmenopausal testosterone therapy.Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review.Phytoandrogenic properties of Eurycoma longifolia as natural alternative to testosterone replacement therapy.Cross-sex hormone therapy for gender dysphoria.Endocrine care of transpeople part II. A review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen.Non-suicidal self-injury and suicidality in trans people: A systematic review of the literature.Pharmacotherapy Considerations in the Management of Transgender Patients: A Brief Review.Cancer in Transgender People: Evidence and Methodological Considerations.Oestrogen and anti-androgen therapy for transgender women.Sociodemographic Antecedent Validators of Suicidal Behavior: A Review of Recent Literature.Thrombotic issues in transgender medicine: A review.Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review.
P2860
Q21135551-A6E8927B-10D4-4CDC-9218-4CC00F66BDDAQ24544067-53DDACA2-82A9-43BF-B245-D56EFE5F2303Q24652232-41FF3734-CADE-4E8C-BC61-CA3EC403D0B2Q26823448-B6807591-E4D1-4305-8D3C-3E632D902FB2Q33716546-9D5EF1CF-BAB8-4325-88FD-F69C6FAE6D4EQ33837116-F0ECA9E9-8B0F-4EF1-83EE-127FC514161AQ33974473-B9ED3AED-255D-4186-88A6-8526AAA2AF81Q34025239-4064EA02-288F-4F4B-838A-3DE2DD052483Q34130823-C21E40BD-5B9A-45BE-B7E8-3C509F73F16AQ34258902-A60ED5F0-B2A2-45DB-BE85-E7DFA2276829Q34259431-0A5DFC0C-FD65-4798-BAFF-D63ABD48318EQ34438584-782B638B-9487-46EA-B030-424AB9B5B10EQ34441141-33DEDE30-13E6-4241-9787-B5B50F121CEFQ34474654-64502A7D-CFA9-4F06-A8BD-0B50F2CF028BQ34516434-AD76DFA4-D4CB-4F63-B7AE-1FEF747FD2DAQ35010632-D95D7576-E81F-45B6-954B-CFC28A62E981Q35181580-777135A9-C099-4BCB-9C4D-D74A8D523779Q35544192-8674EA75-C5D0-459D-B60F-1B7A6AA092F6Q36760469-FAA1449E-1971-4C00-9C9E-A70EF61229F8Q36766910-A3C3E4DE-3839-42A6-89D2-600D42AF70B8Q36770055-1C8FEE24-0F0E-4198-A41E-150034DBB7F8Q36864696-B7BA6303-0A3B-4DA6-97C0-A82352E2D342Q36960860-7A315124-EE94-4BF6-962F-05709DE9FA76Q37037619-295FCE7B-FD37-4802-A6C7-680B63AF9ECBQ37041181-108B4A49-9F6E-44E4-997C-A9219EB193D1Q37088243-E644381F-31D8-4C9B-9F60-171FD4C583CCQ37177962-13378FC5-818F-4482-B70C-F1DE31ABDD33Q37218944-3AFEA7DD-3B57-4D4E-A253-179EEAFF6075Q38007199-7B27E5CA-8AD0-4B37-8281-DBEBCF4F92A6Q38128907-862A969A-B928-44EC-B5A5-B646ADA7C111Q38175427-D597B211-5351-49BE-8329-17B2B0E576FFQ38268810-3B16D4CE-3FB6-43F4-9CEB-F3B26377AFFEQ38360342-215882E9-E8EA-4EB3-83B3-1EDEFD9B4486Q38578371-72A459C9-AF45-4B28-9B57-6229FB240D2EQ38673882-09CE18AA-D2C2-4BFA-8AC5-98DEC922A9EAQ38685944-7E584054-B995-40C0-AF0C-AABB7B628F3DQ38787403-29A4319C-B9DB-4AA7-B827-EC30886D6CC4Q38946656-B7C132AE-1BDA-436F-9D82-018398915AC8Q38990294-49B4C913-6598-41CC-8BDC-9007BBB9A556Q39435553-C4EEDA29-FC24-4CC7-A375-492636CB3EE7
P2860
Mortality and morbidity in transsexual subjects treated with cross-sex hormones.
description
1997 nî lūn-bûn
@nan
1997 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Mortality and morbidity in transsexual subjects treated with cross-sex hormones.
@ast
Mortality and morbidity in transsexual subjects treated with cross-sex hormones.
@en
Mortality and morbidity in transsexual subjects treated with cross-sex hormones.
@nl
type
label
Mortality and morbidity in transsexual subjects treated with cross-sex hormones.
@ast
Mortality and morbidity in transsexual subjects treated with cross-sex hormones.
@en
Mortality and morbidity in transsexual subjects treated with cross-sex hormones.
@nl
prefLabel
Mortality and morbidity in transsexual subjects treated with cross-sex hormones.
@ast
Mortality and morbidity in transsexual subjects treated with cross-sex hormones.
@en
Mortality and morbidity in transsexual subjects treated with cross-sex hormones.
@nl
P2093
P1476
Mortality and morbidity in transsexual subjects treated with cross-sex hormones.
@en
P2093
Asscheman H
van Kesteren PJ
P304
P356
10.1046/J.1365-2265.1997.2601068.X
P577
1997-09-01T00:00:00Z